Non Small Cell Lung Cancer Therapeutics Market Forecast 2015 - 2023


Posted January 14, 2016 by MRRSE16

NSCLC, often the most dreaded of all types of lung cancer, is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases.

 
Report Description

This report on the non-small cell lung cancer (NSCLC) Therapeutics market studies the current and future prospects of the global market. Non-small cell lung cancer is a type of lung cancer which accounted 85-90% of all lung cancers. There are three major subtypes of NSCLC namely squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC is relatively insensitive to chemotherapy compared to small cell lung cancer. Increasing awareness along with incidence rate are expected to propel the global non-small cell lung cancer therapeutics market.

The NSCLC market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global NSCLC therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global NSCLC therapeutics market.

Complete Report with TOC @ www.mrrse.com/non-small-cell-lung-cancer-market

Scope

APAC is anticipated to expand at the fastest CAGR during the forecast period. Factors such as increasing population, greater awareness about NSCLC, and growing number of government projects related to lung, cancer, tobacco, and their respective interventions would boost the growth of the market in APAC during the forecast period.

Key Players

Major players operating in the NSCLC market are Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, AstraZeneca plc, and Celgene Corporation.

Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/1426
s
About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact
Corporate Office
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By MRRSE
Country United States
Categories Business
Tags lung cancer , non small cell lung cancer , non small cell lung cancer marketing
Last Updated January 14, 2016